ArticleFrontiers in immunology2013
The role of the innate immune system in granulomatous disorders.
Article in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 101 citations in OpenAlex.
- Telomere shortening correlates with immune dysregulation and severity in pulmonary tuberculosis.BMC pulmonary medicine · 2026Article
- Eosinophils enhance granuloma-mediated control of persistent Salmonella infection in mice.Nature microbiology · 2025Article
- Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Naringenin attenuates liver injury in Schistosoma mansoni-induced liver fibrosis and oxidative stress in mice model.PLoS neglected tropical diseases · 2025Article
- Review
- Whole exome sequencing for identifying rare genetic variants related to idiopathic granulomatous mastitis.Clinical rheumatology · 2025Article
- Case Report: Atypical extensive orbitofacial tuberculosis extending to the skull base and cavernous sinus revealed major histocompatibility complex class II deficiency in an 11-year-old girl.Frontiers in pediatrics · 2025Article
- Recent advances in immunopathogenesis and clinical practice: mastering the challenge-managing of non-tuberculous mycobacteria.Frontiers in immunology · 2025Review
- Single-cell RNA sequencing analysis reveals cell landscape and gene signatures associated with granulomatous lobular mastitis.Frontiers in immunology · 2025Article
- Breaking barriers: The potential of nanosystems in antituberculosis therapy.Bioactive materials · 2024Review
- A TNF-IL-1 circuit controls Yersinia within intestinal pyogranulomas.The Journal of experimental medicine · 2024Article
- A Rare Clinical Finding in Ataxia Telangiectasia: Granulomatous Skin Lesion.Turkish archives of pediatrics · 2024Article
- Tackling Drug-Resistant Tuberculosis: New Challenges from the Old PathogenMicroorganisms · 2023Review
- A TNF-IL-1 circuit controlsbioRxiv : the preprint server for biology · 2023Article
- Inflammatory monocytes promote granuloma control of Yersinia infection.Nature microbiology · 2023Article
- High Inborn Errors of Immunity Risk in Patients with Granuloma.Journal of clinical immunology · 2022Article
- Immunometabolism of Immune Cells in Mucosal Environment Drives Effector Responses againstInternational journal of molecular sciences · 2022Review
- Article
- Assessment of the toxicity and carcinogenicity of double-walled carbon nanotubes in the rat lung after intratracheal instillation: a two-year study.Particle and fibre toxicology · 2022Article
- Inflammatory Monocytes Promote Granuloma-Mediated Control of Persistent Salmonella Infection.Infection and immunity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dynamic structure of the granuloma serves to protect the body from microbiological challenge. This organized aggregate of immune cells seeks to contain this challenge and protect against dissemination, giving host immune cells a chance to eradicate the threat. A number of systemic diseases are characterized by this specialized inflammatory process and granulomas have been shown to develop at multiple body sites and in various tissues. Central to this process is the macrophage and the arms of the innate immune response. This review seeks to explore how the innate immune response drives this inflammatory process in a contrast of diseases, particularly those with a component of immunodeficiency. By understanding the genes and inflammatory mechanisms behind this specialized immune response, will guide research in the development of novel therapeutics to combat granulomatous diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.